Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H.
Int Clin Psychopharmacol. 2014 Jan;29(1):16-25. doi: 10.1097/YIC.0000000000000011.
Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.
Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.
Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd.
Female reproductive life cycle and hormones: methodology to improve clinical trials.
Freeman MP, Walker R, Laughren TP, Miller KK, Fava M.
J Clin Psychiatry. 2013 Oct;74(10):1018-21.
Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
Trivedi MH, Bandelow B, Demyttenaere K, Papakostas GI, Szamosi J, Earley W, Eriksson H.
Int J Neuropsychopharmacol. 2013 Sep;16(8):1733-44. doi: 10.1017/S146114571300028X. Epub 2013 May 14. Erratum in: Int J Neuropsychopharmacol. 2015;18(2). pii: pyu086. doi: 10.1093/ijnp/pyu086. Papakosts, George I [corrected to Papakostas, George I]. Int J Neuropsychopharmacol. 2015 Jul;18(9). pii: pyv056. doi: 10.1093/ijnp/pyv056.
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
Dording C, Cassiello C, King F 4th, Pencina M, Fava M, Mischoulon D.
Int Clin Psychopharmacol. 2013 Sep;28(5):238-44.
Massachusetts General Hospital SAFER criteria for clinical trials and research.
Desseilles M, Witte J, Chang TE, Iovieno N, Dording C, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D.
Harv Rev Psychiatry. 2013 Sep-Oct;21(5):269-74.
Use of functional imaging across clinical phases in CNS drug development.
Borsook D, Becerra L, Fava M.
Transl Psychiatry. 2013 Jul 16;3:e282. doi: 10.1038/tp.2013.43.
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
Doros G, Pencina M, Rybin D, Meisner A, Fava M.
Stat Med. 2013 Jul 20;32(16):2767-89.
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol.
Thase ME, Montgomery S, Papakostas GI, Bauer M, Trivedi MH, Svedsäter H, Locklear JC, Gustafsson U, Datto C, Eriksson H.
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. Int Clin Psychopharmacol.
2013 May;28(3):113-20. doi: 10.1097/YIC.0b013e32835fb971.
Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies.
Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G, Gomeni R, Lawson E, Lopez M, Millns H, Rabiner EA, Trist D, Trower M, Zamuner S, Krishnan R, Fava M.
J Psychopharmacol. 2013 May;27(5):424-34.
© 2024 Copyright MGH Clinical Trials Network and Institute.
Website design by Tomo360